UNSPSC 51334202: Clothiapine or clotiapine

This classification denotes a serotonin antagonist and dopamine antagonist with the molecular formula C18H18ClN3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z05HCY0X1T, chemically known as 2-chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)thiazepine but generally known as clothiapine, which bears US NIH Compound Identifier 16351. European Medicines Agency schedules Clotiapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06772MIG.

UNSPSC 51334202 Clothiapine or clotiapine is a Commodity code that in practice does not align with recent state and local procurement activity. The source contains three recent opportunities tagged to this code, but none involve clothiapine or clotiapine—a specific antipsychotic pharmaceutical. Instead, the opportunities reflect procurement of naloxone (an opioid antagonist), general generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program design services. The code's nominal scope and the actual work being solicited show no overlap, signaling either a cataloging error in the source or that clothiapine itself does not drive state and local procurement volume.

The three opportunities span different issuing bodies and procurement stages: Seminole County, Florida issued an IFB (solicitation IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; the Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription program models; and the Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products to supply state and local government facilities across multiple states including Oregon. Activity appears concentrated in health and human services procurement—state pharmacy benefit programs, county community health initiatives, and cooperative purchasing alliances—but no meaningful recent opportunities specifically target clothiapine or clotiapine procurement.